Compare TPVG & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPVG | CGEN |
|---|---|---|
| Founded | 2013 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 224.9M | 201.8M |
| IPO Year | 2013 | 2001 |
| Metric | TPVG | CGEN |
|---|---|---|
| Price | $4.39 | $1.97 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $5.83 | $4.60 |
| AVG Volume (30 Days) | ★ 187.3K | 174.7K |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | ★ 20.81% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.96 | N/A |
| P/E Ratio | $10.28 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.39 | $1.43 |
| 52 Week High | $6.95 | $3.24 |
| Indicator | TPVG | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 28.19 | 31.86 |
| Support Level | N/A | $1.98 |
| Resistance Level | $4.96 | $2.37 |
| Average True Range (ATR) | 0.13 | 0.09 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 5.56 | 10.89 |
TriplePoint Venture Growth BDC Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize its total return to stockholders in the form of current income and, to a lesser extent, capital appreciation. The fund focuses on companies operating in the fields of biofuels, business applications software, wireless communications equipment, e-commerce, clothing and accessories, conferencing equipment and services, personal goods, financial institutions and services, entertainment, mixed retailing, and healthcare services. Geographically, all the firm's operations are located across the United States.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.